☰

Min Yang, Ph.D. - Publications

Affiliations: 
University of Virginia, Charlottesville, VA 
Area:
Bioorganic and Synthetic Organic Chemistry
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Xing X, Ai C, Wang T, Li Y, Liu H, Hu P, Wang G, Liu H, Wang H, Zhang R, Zheng J, Wang X, Wang L, Chang Y, Qian Q, ... ... Yang M, et al. The first high-quality reference genome of sika deer provides insights for high-tannin adaptation. Genomics, Proteomics & Bioinformatics. PMID 35718271 DOI: 10.1016/j.gpb.2022.05.008  0.311
2017 Silva J, Kalinsky K, Quayle S, Yang M. Abstract P3-07-06: Inhibition of HDAC6 as targeted therapy for breast cancers Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-07-06  0.32
2016 Huang P, Almeciga-Pinto I, Yang M, Jones SS, Quayle SN. Abstract 4822: Combination efficacy of the selective HDAC inhibitor ACY-241 and paclitaxel in solid tumor models Cancer Research. 76: 4822-4822. DOI: 10.1158/1538-7445.Am2016-4822  0.348
2016 Min C, Quayle SN, Huang P, Shearstone JR, Jones SS, Yang M. Abstract 4724: Novel and selective inhibitors of histone deacetylases (HDAC) 1 and 2 synergize with DNA methyltransferase inhibitor azacitidine in acute myeloid leukemia (AML) Cancer Research. 76: 4724-4724. DOI: 10.1158/1538-7445.Am2016-4724  0.341
2016 Tamang DL, Huang P, Golonzhka O, Shearstone JR, Quayle SN, Jones SS, Yang M. Abstract 2477: An orally bioavailable and selective histone deacetylase (HDAC) 1 & 2 inhibitor enhances retinoic acid mediated differentiation of neuroblastoma Cancer Research. 76: 2477-2477. DOI: 10.1158/1538-7445.Am2016-2477  0.322
2015 Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, et al. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research : Bcr. 17: 149. PMID 26643555 DOI: 10.1186/S13058-015-0658-0  0.322
2015 Quayle SN, Almeciga-Pinto I, Tamang D, Yang M, Jones SS. Abstract 5380: Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD® immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells Cancer Research. 75: 5380-5380. DOI: 10.1158/1538-7445.Am2015-5380  0.359
2015 Min C, Quayle SN, Tamang D, Jones SS, Yang M. Abstract 5372: Novel and selective inhibitors of histone deacetylases (HDAC) 1 and 2 significantly enhance the activity of the DNA methyltransferase inhibitor azacitidine in acute myeloid leukemia (AML) Cancer Research. 75: 5372-5372. DOI: 10.1158/1538-7445.Am2015-5372  0.345
2015 Min C, Quayle SN, Huang P, Shearstone JR, Jones SS, Yang M. Abstract B84: Novel and selective inhibitors of histone deacetylases (HDAC) 1 and 2 significantly enhance the activity of the DNA methyltransferase inhibitor azacitidine in acute myeloid leukemia (AML) Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B84  0.352
2015 Huang P, Almeciga-Pinto I, Jordan M, Yang M, Jones SS, Quayle SN. Abstract A187: Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A187  0.351
2015 Tamang DL, Haung P, Golonzhka O, Shearstone J, Quayle SN, Jones SS, Yang M. Abstract A136: A novel, orally bioavailable and selective histone deacetylase (HDAC) 1 & 2 inhibitor enhances retinoic acid mediated differentiation of neuroblastoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A136  0.314
2014 Quayle SN, Tamang D, Yang M, Jones SS. Abstract 5456: ACY-1215, a selective inhibitor of HDAC6, synergizes with immunomodulatory drugs (IMiDs) to induce apoptosis of multiple myeloma (MM) cells Cancer Research. 74: 5456-5456. DOI: 10.1158/1538-7445.Am2014-5456  0.35
2013 Berger AJ, Bannerman B, Quayle SN, Yu J, Garcia K, Ciavarri J, Tamang D, Yang M, Jones SS. Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models Blood. 122: 4437-4437. DOI: 10.1182/Blood.V122.21.4437.4437  0.317
2013 Tamang D, Jones SS, Yang M, Supko J. Tubulin Hyper-Acetylation In Blood Lymphocytes: Pharmacodynamic (PD) Biomarker For The Selective Histone Deacetylase (HDAC) 6 Inhibitor ACY-1215 In Multiple Myeloma (MM) Patients Blood. 122: 3219-3219. DOI: 10.1182/Blood.V122.21.3219.3219  0.313
2013 Quayle SN, Tamang D, Yang M, Jones SS. Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells Blood. 122: 3071-3071. DOI: 10.1182/Blood.V122.21.3071.3071  0.322
2013 Yang M, Tamang D, Jones SS, Cheng Z, Chirn G. Discovery Histone Deacetylase (HDAC)6 Specific Proteomic Biomarkers In Multiple Myeloma (MM) Using Stable Isotope Labeling By Amino Acids In Cell Culture (SILAC) Blood. 122: 1909-1909. DOI: 10.1182/Blood.V122.21.1909.1909  0.324
2013 Yang M, Tamang D, Jones SS, Di L. Abstract LB-120: Large-scale cancer cell line screening with a novel and selective HDAC-6 inhibitor (ACY-1215) identifies candidate predictive biomarkers for breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-120  0.34
2011 Santo L, Hideshima T, Kung AL, Tseng J, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea DD, Rodig S, Eda H, Scullen TA, Canavese M, et al. Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma Blood. 118: 2912-2912. DOI: 10.1182/Blood.V118.21.2912.2912  0.344
2011 Santo L, Hideshima T, Kung AL, Tseng J, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Cirstea D, Eda H, Scullen TA, Rodig S, Canavese M, Bradner J, et al. Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma Blood. 118: 2908-2908. DOI: 10.1182/Blood.V118.21.2908.2908  0.311
2010 Yang M, Chordia MD, Li F, Huang T, Linden J, MacDonald TL. Neutrophil- and myeloperoxidase-mediated metabolism of reduced nimesulide: Evidence for bioactivation Chemical Research in Toxicology. 23: 1691-1700. PMID 20939553 DOI: 10.1021/Tx1001496  0.548
Show low-probability matches.